{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:38:46Z","timestamp":1772260726910,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,8,2]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Non\u2010high\u2010density lipoprotein cholesterol (non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low\u2010density lipoprotein cholesterol alone.\n              <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>\n              and European lipid management guidelines support non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoB as targets for lipid\u2010lowering therapy.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              This analysis evaluated the efficacy of alirocumab, a proprotein convertase subtilisin\/kexin type 9 inhibitor, on non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoB. Data were derived from 4983 patients enrolled in 10 randomized, placebo\u2010 or ezetimibe\u2010controlled Phase 3\n              <jats:styled-content style=\"fixed-case\">ODYSSEY<\/jats:styled-content>\n              trials. Primary end point for this pooled analysis was percent reduction in non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoB at Week 24; secondary end points included the percentage of patients achieving guideline\u2010directed treatment goals (National Lipid Association guidelines: non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C &lt;100 or &lt;130\u00a0mg\/dL for patients at very high and high cardiovascular risk, respectively; European Society of Cardiology\/European Atherosclerosis Society guidelines: apoB &lt;80\u00a0mg\/dL for patients at very\u2010high cardiovascular risk). Data were grouped according to comparator, alirocumab starting dose, and concomitant statin use. Compared with controls, alirocumab produced significantly greater reductions in non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoB at Week 24 (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.0001), an effect extending up to 78\u00a0weeks. More alirocumab\u2010treated patients achieved levels of non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C &lt;100\u00a0mg\/dL and apoB &lt;80\u00a0mg\/dL (\n              <jats:italic>P<\/jats:italic>\n              \u22640.0001 versus control). By Week 24, &gt;70% of alirocumab\u2010treated patients on background statin achieved non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C &lt;100 or &lt;130\u00a0mg\/dL, and apoB &lt;80\u00a0mg\/dL. Safety was comparable across pooled groups and in line with previous reports.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Alirocumab produced significant, sustained reductions in non\u2010\n              <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n              \u2010C and apoB, allowing more patients to achieve lipid goals compared with placebo or ezetimibe and irrespective of maximally tolerated statin use.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.117.005639","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T18:25:38Z","timestamp":1504290338000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Alirocumab Treatment and Achievement of Non\u2010High\u2010Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials"],"prefix":"10.1161","volume":"6","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[{"name":"Louisville Metabolic and Atherosclerosis Research Center (L\u2010MARC), Louisville, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"University of Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[{"name":"Western General Hospital, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond","family":"Thompson","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bessac","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[{"name":"CGH Medical Center, Sterling, IL"},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S2364"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.07.005"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.002"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1520"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.11.010"},{"key":"e_1_3_4_11_2","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein JJ","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara\u2010Dinet MT, Gipe DA, Geiger MJ, Farnier M. ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996\u20133003.","journal-title":"Eur Heart J"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.06.049"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.08.273"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.09.010"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.08.072"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.037"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.713438"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2013.11.001"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.055"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.045"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487315569411"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000759"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.366"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.959247"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.024"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1619"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.057"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.07.007"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024604"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.117.005639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:54:18Z","timestamp":1715597658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.117.005639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8,2]]}},"alternative-id":["10.1161\/JAHA.117.005639"],"URL":"https:\/\/doi.org\/10.1161\/jaha.117.005639","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]},"assertion":[{"value":"2017-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e005639"}}